February 24, 2025

S12 Ep17: Triplet Chemo Trial Raises Importance of Accurately Defined Subgroups in Biliary Tract Cancer Research: With Rachna Shroff, MD, MS, FASCO

11 minutes

In today’s episode, we had the pleasure of speaking with Rachna Shroff, MD, MS, FASCO, about the phase 3 SWOG S1815 trial (NCT03768414) evaluating the addition of nab-paclitaxel (Abraxane) to gemcitabine and cisplatin in patients with newly diagnosed, advanced biliary tract cancer. Dr Shroff of the interim clinical affairs director, the associate director of Clinical Investigations, and co-lead of the Gastrointestinal Clinical Research Team, at The University of Arizona Cancer Center. She is also a professor in the Department of Medicine, chief of the Division of Hematology/Oncology, medical director for the Oncology Service Line, and associate dean for Clinical and Translational Research at The University of Arizona College of Medicine in Tucson.

In our exclusive interview, Dr Shroff discussed the rationale for this research, key efficacy and safety data from the trial, and the potentially wide-reaching future implications of these findings.

...more

View all episodes

By OncLive® On Air

4.3

2222 ratings

February 24, 2025

S12 Ep17: Triplet Chemo Trial Raises Importance of Accurately Defined Subgroups in Biliary Tract Cancer Research: With Rachna Shroff, MD, MS, FASCO

11 minutes

In our exclusive interview, Dr Shroff discussed the rationale for this research, key efficacy and safety data from the trial, and the potentially wide-reaching future implications of these findings.

...more